CH219010A - Process for the preparation of a solid molecular compound containing mercury. - Google Patents
Process for the preparation of a solid molecular compound containing mercury.Info
- Publication number
- CH219010A CH219010A CH219010DA CH219010A CH 219010 A CH219010 A CH 219010A CH 219010D A CH219010D A CH 219010DA CH 219010 A CH219010 A CH 219010A
- Authority
- CH
- Switzerland
- Prior art keywords
- molecular compound
- solution
- mercury
- compound
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 9
- 239000007787 solid Substances 0.000 title claims description 8
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 title claims description 7
- 229910052753 mercury Inorganic materials 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 229940100892 mercury compound Drugs 0.000 claims description 9
- 150000002731 mercury compounds Chemical class 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 229960000278 theophylline Drugs 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- -1 alkyl purines Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/10—Mercury compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Verfahren zur Herstellung einer festen quecksilberhaltigen 3Tolekularverbindung. Verfahren zur Herstellung von aus kom plexen Quecksilberverbindungen und Alkyl- purinen bestehenden Molekularverbindungen in gelöster Form werden in der Praxis seit langem ausgeführt. Sie bestehen darin, dass man Salze komplexer Quecksilberverbindungen und das entsprechende Alkylpurin in Wasser löst.
Diese Arzneiform ist natürlich nur für die parenterale Verabfolgung dieser therapeu tischen Mittel geeignet und lässt sich für an dere Arzneiformen, etwa für die Tabletten- oder die Suppositorien-Form, nicht unmittelbar verwenden. Man war also darauf angewiesen, statt der Molekularverbindungen die einzelnen Komponenten in fester Form zu mischen und diese Mischungen weiter zu verarbeiten. Diese Massnahme hat aber den grossen Nachteil, dass die so gewonnenen Präparate nicht reizlos vertragen werden.
Es wurde nun gefunden, dass es gelingt, eine feste quecksilberhaltige Molekularverbin- dung herzustellen, wenn man die komplexe Quecksilberverbindung des salicylallylamido- essigsauren Natriums der Formel
EMI0001.0018
und Theophyllin in wässriger Lösung aufein ander einwirken lässt und aus der Lösung die entstandene Molekularverbindung in fester Form ausscheidet, vorzugsweise durch Zusatz geeigneter fällender Lösungsmittel oder durch Eindampfen der Lösung zur Trockne.
Man kann das Verfahren beispielsweise so ausführen, dass man die wässrige Lösung der komplexen Quecksilberverbindung und des Theophyllins, zweckmässig nach teilweisem Eindampfen, mit Alkohol und Äther versetzt; dabei scheidet sich die Molekularverbindung unmittelbar in fester Form ab und kann durch Zentrifugieren oder Absaugen abgetrennt wer den. Man kann aber mit Vorteil auch so vor gehen, dass man die wässrige Lösung zur Trockne eindampft, was gegebenenfalls im Vakuum geschehen kann.
Es ist bereits bekannt (vergl. Chem. Zen tralblatt 1929, I, Seite 1696 f, und 1934, I, 3858, sowie deutsche Patentschrift. 538375), quecksilberhaltige Verbindungen von Purinen herzustellen, in denen das Quecksilber am Purinkern haftet. Ferner sind durch die deut sche Patentschrift 637188 sowie die britischen Patentschriften 447405 und 443517 komplexe Quecksilberverbindungen mit Purinen bereits bekannt geworden.
Die überraschende Wirkung des hier be schriebenen neuen Verfahrens besteht jedoch darin, dass man aus einer in Trockenform hygroskopischen und daher nicht haltbaren komplexen Quecksilberverbindung des salicyl- allylamido-essigsauren Natriums, das überdies gegen die Einwirkung reduzierender Mittel überaus empfindlich ist, durch Überführung in eine Molekülverbindung mit dem Theo- phyllin eine, wie sich zeigte, gegen reduzierende Mittel weit weniger empfindliche, völlig luft beständige und nicht mehr hygroskopische Verbindung herstellen kann, die unbegrenzt haltbar ist.
Aus dieser, wie sich ergab, reiz los verträglichen Molekularverbindung lassen sich beliebige Arzneiformen, beispielsweise Tabletten oder Suppositorien herstellen, ohne dass die Gefahr einer Abscheidmig von Queck silber bestünde. <I>Beispiele:</I> 1. 100 g der komplexen Quecksilberver bindung des salicyla.llylamido-essigsaui,eii Na triums von der oben angegebenen Formel und 45 g Theophyllin werden in 1 Liter Wasser gelöst, diese Lösung mit der zehnfachen Menge Äthylalkohol verdünnt und unter Rühren mit Äther bis zur bleibenden Trübung versetzt.
Beim Stehen scheidet sich ein farbloser, kri stallinischer Niederschlag aus, der abgesaugt, mit Äther gewaschen und im Vakuum ge trocknet wird. Die Verbindung ist. ein farb loses, luftbeständiges Pulver; es löst sich leicht und klar in Wasser mit curcum.i-al- kalischer Reaktion und ist unlöslich in Äther und Aceton.
Dasselbe Produkt wird erhalten, wenn die wässrige Lösung unmittelbar mit Aceton ge fällt und der farblose, pulverige Niederschlag abgesaugt und mit Aceton gewaschen wird. 2. Eine Lösung von 300 g der komplexen Quecksilberverbindung des salieylallylamido- essigsauren Natriums von der oben ange gebenen Formel und 135 g Theophyllin wer den in 3 Liter Wasser gelöst und mit oder ohne Vakuum zur Trockne eingedampft, dabei erstarrt der Rückstand zu einer farblosen Kristallmasse, die sich leicht pulvern lässt. Das so erhaltene Produkt zeigt dieselben Eigenschaften wie das nach Beispiel 1 dar gestellte Produkt.
Process for the production of a solid 3-molecular compound containing mercury. Processes for the preparation of molecular compounds consisting of complex mercury compounds and alkyl purines in dissolved form have been carried out in practice for a long time. They consist of dissolving salts of complex mercury compounds and the corresponding alkyl purine in water.
This dosage form is of course only suitable for the parenteral administration of these therapeutic agents and cannot be used directly for other dosage forms, for example for the tablet or suppository form. It was therefore necessary to mix the individual components in solid form instead of the molecular compounds and to process these mixtures further. However, this measure has the major disadvantage that the preparations obtained in this way cannot be tolerated without irritation.
It has now been found that a solid mercury-containing molecular compound can be produced if the complex mercury compound of sodium salicylallylamidoacetic acid of the formula
EMI0001.0018
and theophylline in aqueous solution can act on one another and the resulting molecular compound is precipitated in solid form from the solution, preferably by adding suitable precipitating solvents or by evaporating the solution to dryness.
The process can be carried out, for example, by adding alcohol and ether to the aqueous solution of the complex mercury compound and theophylline, expediently after partial evaporation; the molecular compound separates out immediately in solid form and can be separated off by centrifugation or suction. However, it is also advantageous to proceed in such a way that the aqueous solution is evaporated to dryness, which can optionally be done in vacuo.
It is already known (see Chem. Zen tralblatt 1929, I, page 1696 f, and 1934, I, 3858, and German patent. 538375) to produce mercury-containing compounds of purines in which the mercury adheres to the purine core. Furthermore, complex mercury compounds with purines are already known from German patent specification 637188 and British patents 447405 and 443517.
However, the surprising effect of the new process described here consists in the fact that a complex mercury compound of salicylallylamido-acetic acid sodium, which is hygroscopic in dry form and therefore not durable, and which is also extremely sensitive to the action of reducing agents, is converted into a molecular compound With theophylline, as has been shown, a compound that is far less sensitive to reducing agents, completely air-resistant and no longer hygroscopic, can be established, which is indefinitely durable.
It has been found that this molecular compound, which is tolerated without irritation, can be used to produce any desired dosage forms, for example tablets or suppositories, without the risk of mercury being deposited. <I> Examples: </I> 1. 100 g of the complex Mercury compound of salicyla.llylamido-acetic acid, a sodium of the formula given above and 45 g of theophylline are dissolved in 1 liter of water, this solution with ten times the amount of ethyl alcohol diluted and, while stirring, mixed with ether until it remained cloudy.
A colorless, crystalline precipitate separates out on standing and is filtered off with suction, washed with ether and dried in vacuo. The connection is. a colorless, air-resistant powder; it dissolves easily and clearly in water with a curcum.i-alkaline reaction and is insoluble in ether and acetone.
The same product is obtained when the aqueous solution is immediately precipitated with acetone and the colorless, powdery precipitate is filtered off with suction and washed with acetone. 2. A solution of 300 g of the complex mercury compound of salieylallylamido-acetic acid sodium of the formula given above and 135 g of theophylline are dissolved in 3 liters of water and evaporated to dryness with or without vacuum, the residue solidifies to a colorless crystal mass, which can be easily powdered. The product thus obtained shows the same properties as the product presented according to Example 1.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH219010T | 1938-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH219010A true CH219010A (en) | 1942-01-15 |
Family
ID=4450944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH219010D CH219010A (en) | 1938-11-29 | 1938-11-29 | Process for the preparation of a solid molecular compound containing mercury. |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH219010A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601461A (en) * | 1949-05-20 | 1952-06-24 | Wm S Merrell Co | N-[2-methoxy-3-(alpha, beta-dicarboxyethyl-mercaptomercuri)-propyl]-o-carboxymethylsalicylamide |
US2685594A (en) * | 1952-04-04 | 1954-08-03 | Sterling Drug Inc | Mercury compounds of 2-(nu-allylcarbamyl) phenoxyacetic acid, salts thereof, and method for preparing same |
-
1938
- 1938-11-29 CH CH219010D patent/CH219010A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601461A (en) * | 1949-05-20 | 1952-06-24 | Wm S Merrell Co | N-[2-methoxy-3-(alpha, beta-dicarboxyethyl-mercaptomercuri)-propyl]-o-carboxymethylsalicylamide |
US2685594A (en) * | 1952-04-04 | 1954-08-03 | Sterling Drug Inc | Mercury compounds of 2-(nu-allylcarbamyl) phenoxyacetic acid, salts thereof, and method for preparing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH219010A (en) | Process for the preparation of a solid molecular compound containing mercury. | |
DE1915497A1 (en) | Medicines with hypolipidemic and hypocholesterolemic activity | |
DE675674C (en) | Process for the production of solid molecular compounds consisting of the complex mercury compound of salicylallylamido-acetic acid sodium and alkyl purines | |
US2161114A (en) | Soluble double salts of theophylline and monoamino polyhydric alcohols | |
DE929665C (en) | Process for the preparation of therapeutically active streptomycin and dihydrostreptomycin salts | |
DE734957C (en) | Process for the production of p-aminobenzenesulfonamide pellets | |
DE2408372C3 (en) | Therapeutically acceptable salts of p-chlorohippuric acid and pharmaceutical preparations containing these or p-chlorohippuric acid | |
DE2238260C3 (en) | Phosphoric acid monoester of 5- (2-dimethylaminoethoxy) -carvacrol, process for its preparation and pharmaceuticals containing it | |
AT326127B (en) | PROCESS FOR THE PREPARATION OF NEW QUATERNATED EASTERS OF NICOTINE ACID WITH POLYSACCHARIDES | |
DE738499C (en) | Process for the preparation of addition compounds of hexamethylenetetramine | |
AT311332B (en) | Process for the preparation of a new ester of 3,3-bis (p-hydroxyphenyl) -2-indolinone and its salts | |
AT265243B (en) | Process for the preparation of new salts of p-chlorophenoxyisobutyric acid | |
DE859790C (en) | Process for increasing the solubility of sulfonamides | |
DE2949594C2 (en) | Kanamycin tannate, process for its preparation and pharmaceutical agents | |
DE1568924C (en) | Proscillaridine ketals and process for their preparation | |
DE946539C (en) | Process for the production of new mercury-containing dioxypropane compounds | |
DE2235400C3 (en) | ^ Chlor-S-sulfamoyl-anthranilic acids, their salts, processes for the preparation of these compounds and medicaments containing these compounds | |
DE1023767B (en) | Process for the production of water-soluble, stable penicillin-rutin compounds | |
DE948185C (en) | Process for the production of durable water-soluble products from soluble salts of p-naphthionic acid with adrenochrome compounds | |
DE682021C (en) | Process for the preparation of durable complex gold compounds of catechol disulfonic acid | |
DE1001455B (en) | Process for the production of tasteless preparations of basic antihistamines | |
DE1018052B (en) | Process for the preparation of antimony complex compounds of ª ‡, ª ‡ '-Dimercaptosuccinic acid | |
DE2204986A1 (en) | Water-soluble adducts of strophanthidine and - diethylaminomethyl rutin derivs - useful as oral cardioactive agents | |
DE2238260B2 (en) | Phosphoric acid monoester of 5- (2-dimethylamlnoethoxy) -carvacrol, process for its preparation and medicaments containing them | |
CH648840A5 (en) | Alcohol complexes of 4-hydroxycoumarin derivatives and process for their preparation |